Literature DB >> 2686919

Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of post-cesarean section endometritis.

M G Martens1, S Faro, H A Hammill, D Smith, G Riddle, M Maccato.   

Abstract

Sixty-seven patients diagnosed with post-cesarean-section endometritis were studied in a prospective comparative randomized trial of sulbactam/ampicillin, a new beta-lactamase inhibitor drug combination, versus treatment with metronidazole/gentamicin. The success rate was 91% for each antibiotic regimen. Mycoplasma spp. or Ureaplasma spp. were isolated from all treatment failures. Endometrial cultures revealed 2.3 aerobes as well as anaerobes per patient, with Enterococcus faecalis, Bacteroides bivius, and Escherichia coli the most frequently reported bacterial isolates in 64, 40, and 28% of all patients, respectively. Positive blood cultures were noted in 11 (15%) patients with Mycoplasma sp. the most commonly found isolate (45.5%). Sulbactam/ampicillin appears to be safe and equally effective as a metronidazole/aminoglycoside drug regimen in the treatment of postpartum endometritis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2686919     DOI: 10.1016/0732-8893(89)90135-1

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  3 in total

Review 1.  Antibiotic regimens for postpartum endometritis.

Authors:  A Dhanya Mackeen; Roger E Packard; Erika Ota; Linda Speer
Journal:  Cochrane Database Syst Rev       Date:  2015-02-02

2.  Comparison of fixed concentration and fixed ratio options for dilution susceptibility testing of gram-negative bacilli to ampicillin and ampicillin/sulbactam.

Authors:  M A Pfaller; A L Barry; P C Fuchs; E H Gerlach; D J Hardy; J C McLaughlin
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-05       Impact factor: 3.267

Review 3.  Ampicillin/sulbactam: current status in severe bacterial infections.

Authors:  Petros I Rafailidis; Eleni N Ioannidou; Matthew E Falagas
Journal:  Drugs       Date:  2007       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.